Clinical trials
Prostatic Cancer clinical trials
Below are recruiting prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,219 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Gilbert, ArizonaAges 18 years+ - NCT03753243RecruitingPhase 2
Pembrolizumab and hormone blocker before prostate surgery
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
Portland, OregonAges 18 years+ - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT03789253Recruiting
Tracking genetic changes as low-risk prostate cancer becomes riskier
This study looks for genes and biological pathways that may explain why some men’s prostate cancer grows from low risk to higher risk. You may be followed using planned prostate biopsies after an initial low-risk diagnosis managed with active surveillance.
TaipeiAges 40–100 - NCT03802851Recruiting
Laser procedure before radiation for prostate cancer symptoms
This trial looks at whether doing a prostate “laser procedure” (called HoLEP) before starting radiation and hormone therapy can improve severe urinary symptoms and reduce urine retention problems. It is for people with prostate cancer who are planning radiation plus hormone treatment and who have significant bladder/urinary trouble.
Kansas City, KansasAges 18 years+ - NCT03819101RecruitingPhase 3
Aspirin plus atorvastatin for advanced, treatment-resistant prostate cancer
This trial studies whether daily aspirin and atorvastatin can slow advanced prostate cancer that has continued to grow despite hormone therapy. It may help by reducing cancer growth and inflammation, but you would need to meet several specific safety and medication rules.
OlomoucAges 18 years+ - NCT03819751Recruiting
MRI-guided prostate biopsy: software vs visual matching
This study compares two ways of using prostate MRI images to guide a biopsy and check how accurately prostate cancer can be found. If you have MRI spots that may be cancer, the trial will help test whether computer software or a visual method works better.
Leuven, Vlaams-brabantAges 50–75 - NCT03821246RecruitingPhase 2
Atezolizumab and other drugs before prostate surgery for high-risk cancer
This Phase 2 trial tests whether giving immunotherapy (atezolizumab) plus another drug before surgery can shrink or control high-risk localized prostate cancer. The goal is to improve outcomes by treating the cancer early, before radical prostatectomy.
San Francisco, CaliforniaAges 18 years+ - NCT03833921RecruitingPhase 2
Testing abiraterone and prednisone for metastatic prostate cancer by race
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
Houston, TexasAges 18 years+ - NCT03880422Recruiting
Exercise and nutrition for weight and frailty after prostate cancer treatment
This study tests whether a structured exercise and nutrition program can improve obesity-related frailty and overall function in people with advanced prostate cancer who are taking hormone therapy (ADT). It may help with strength, mobility, and healthier body weight during/after ADT.
Buffalo, New YorkAges 18 years+ - NCT03893929Recruiting
Test new markers to help diagnose prostate cancer
This study looks for new biological markers in men to improve how prostate cancer is diagnosed and followed. If you have signs that might be prostate cancer, your tests may help researchers find better clues for future care.
ShatinAges 18 years+ - NCT03908684Recruiting
Ultrasound tests to predict early response to prostate and head/neck radiation
This study uses special ultrasound imaging to look for early signs of how well radiation treatment is working in prostate, rectum, and head/neck cancers. It may help doctors spot response sooner and adjust care earlier if needed.
Toronto, OntarioAges Any age - NCT03914391Recruiting
Find new urine tests to screen for prostate cancer
This study looks for new urine markers (signals) that could help screen for prostate cancer. If you have a higher PSA blood test and are scheduled for a prostate biopsy, your urine sample may be studied to see if it can improve screening.
ShatinAges 18 years+ - NCT03933670RecruitingPhase 2
MRI scan with special sugar to monitor prostate cancer on surveillance
This study uses a special MRI scan using “hyperpolarized” labeled pyruvate (a sugar-like substance) to see how prostate cancer may be behaving in people who are on active surveillance. It may help researchers monitor cancer without immediate treatment, by spotting changes earlier.
San Francisco, CaliforniaAges 18 years+ - NCT04004312Recruiting
Short-course radiation slices for localized prostate cancer
This trial tests a radiation approach that delivers treatment in a small number of larger “fractions” (short-course SBRT) for prostate cancer. It may help by targeting the prostate while shortening the overall number of visits.
Montreal, QuebecAges 18 years+ - NCT04340024Recruiting
Testing blood markers linked to how well radiation works
This study looks for “biomarkers,” or measurable signs (often from blood or samples), that may show which cancers respond better to radiation therapy. It may help doctors choose radiation treatment more precisely, especially for people who had significant side effects before.
SingaporeAges 21–99 - NCT07581184RecruitingPhase 1
Targeted Radioactive Therapy for Advanced Prostate Cancer
This Phase 1 trial tests a new radioactive treatment called [225Ac]Ac-AKY-2519 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug carries radioactivity directly to cancer cells to try to shrink tumors and slow disease progression.
Irvine, CaliforniaAges 18 years+ - NCT04075305Recruiting
Study measuring radiation treatment outcomes with an MR-Linac
This study follows what happens when radiation treatment is guided using an MR-Linac (a special machine that combines MRI imaging with radiation). It may help improve how radiation therapy is planned and assessed, especially for people who can safely have MRI scans.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04146077Recruiting
Active monitoring for low-risk prostate cancer
This study tests whether watching low-risk prostate cancer closely (instead of treating right away) is safe. It may help some people avoid early treatments and their side effects while still keeping a close eye on the cancer.
MoscowAges 50–75 - NCT04172753Recruiting
Online MRI-guided radiation therapy on a 1.5T machine
This trial checks whether it’s practical and safe to deliver radiation treatment using real-time MRI guidance, with the process supported online. It may help patients whose doctors recommend radiation by testing a modern way to plan and deliver treatment more precisely.
Tübingen, Baden-WurttembergAges 18 years+ - NCT04221542RecruitingPhase 1
AMG 509 for advanced, hormone-resistant prostate cancer
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Duarte, CaliforniaAges 18 years+ - NCT04231006Recruiting
High-dose salvage radiation for prostate cancer that came back locally
This trial studies high-dose radiation (HDR) given after prostate cancer returns only in the prostate/seminal vesicles. It may help by trying to control the cancer when it has not spread elsewhere, using targeted treatment based on MRI and biopsy proof.
Aarhus, Region MidtAges 18 years+ - NCT04249154RecruitingPhase 2
After prostate surgery, test radiation plus hormone shots
This trial studies whether giving a shorter-course radiation plan after prostate surgery, along with hormone shots (LHRH), can improve outcomes for people with higher-risk prostate cancer. You may be eligible if your PSA (a blood marker) is either still low but high-risk by pathology, or it has started to rise again after surgery.
Montreal, QuebecAges 18 years+ - NCT04337580RecruitingPhase 2
Test a fatty-acid drug for docetaxel-resistant prostate cancer
This Phase 2 study tests whether blocking fatty-acid production can slow castration-refractory prostate cancer that has already progressed after docetaxel. It may help by targeting cancer growth when standard hormone-level treatments are no longer working.
Salisbury, North CarolinaAges 18 years+
Hear when a new Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatic cancer?
- Yes. Clin2 currently lists 1,219 recruiting prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.